Automated And Closed Cell Therapy Processing System Market Size, Share, and Trends 2024 to 2034

The global automated and closed cell therapy processing system market size reached at USD 997.4 million in 2022 and it is expected to hit around USD 8,201.33 million by 2032, growing at a CAGR of 23.45% from 2023 to 2032. The growing demand for regenerative medicines is considered to fuel the growth of the global automated and closed-cell therapy processing system market.

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways:

• North America generated more than 46% of the revenue share in 2022.
• By workflow, the expansion segment dominates the market and captures more than 35% of the revenue share in 2022. 
• By workflow, the apheresis segment is projected to witness remarkable growth between 2023 and 2032.
• By type, the non-stem cell therapy segment dominates the market and generated more than 60% of the revenue share in 2022.
• By scale, The Research and development (R&D) scale segment captured more than 70% of the revenue share in 2022.
• By scale, the commercial scale segment is expected to register remarkable growth from 2023 to 2032.

Automated and Closed Cell Therapy Processing System Market Overview:

Automation in cell therapy processing or manufacturing systems has offered unmatched advantages to the global pharmaceutical industry. The cell therapy manufacturing process includes the selection, isolation, modification and expansion of the cells. Any minor error in this whole complex procedure may cause improper infusion of cells. The automated and closed cell therapy processing systems de-risk the final formulation. Automation in cell therapy processing reduces the chances of contamination led by the manual procedure. The automated and closed cell therapy processing system is used to enhance the scale of cell operations by reducing the risk of errors during bioprocessing.

The rising prevalence of cancer across the globe has increased the demand for automated and closed-cell therapy processing systems. The fully automated cell therapy processing systems aim to achieve robust processing with improved therapies for highly untreatable diseases. The prominent companies in the global automated and closed cell therapy processing systems market are supplementing the market’s development by introducing advanced platforms for the cell therapy manufacturing process.

Growth Factors:

The global automated and closed cell therapy processing systems market is expected to witness a significant increase during the projected timeframe owing to the continuously developing global pharmaceutical industry. The revolutionization of gene therapy and cell therapy has supplemented the development of the market in recent years. The rising commercialization of cell therapies around the world is considered to boost the market’s growth in the upcoming years. 

The utilization of automated and closed cell therapy processing systems has effectively reduced labor cost, this factor is also considered for offering profitable advantages to the market. At the same time, the development of the market is propelled by factors such as the rising demand for regenerative medicines and customized therapies across the globe. 

The automated and closed cell therapy processing systems have offered the enhanced speed of manufacturing with high-quality outputs; this adventitious factor is fueling the market’s development. Moreover, the Covid-19 pandemic has highlighted the advantages of stem cell therapy; the advancements in stem cell therapies are expected to continue during the forecast period by boosting the growth of the automated and closed cell therapy processing system market. However, the time-consuming and expensive cell therapy manufacturing process is considered to restrain the market’s growth.  

Automated and Closed Cell Therapy Processing System Market Scope:

Automated and Closed Cell Therapy Processing System Market Dynamics:

Driver:

Rising demand for regenerative medicine

Regenerative medicine is a field of medicine that replaces damaged tissues or organs. Basically, regenerative medicine deals with replacing and restoring tissue or organ damage due to a particular disease or accident. The increasing demand for regenerative medicine from the healthcare sector is a significant driving factor for the growth of automated and closed-cell therapy processing systems, owing to the rising importance of stem cells in regenerative medicine. 

The increasing cases of cancer and other chronic diseases that require prolonged treatment have boosted the popularity of regenerative medicine. Regenerative medicine consists of stem cell applications. Stem cells have indefinite cell division potential and are used as a frontline source for regenerative medicine.  

Restraint:

Shortage of raw materials:

The entire cell therapy manufacturing procedure consists of various steps which require starting material. The rising demand for automated and closed cell therapy processing systems across the globe has created a shortage of raw materials that are necessary for good medical practice (GMP). Due to the rapid increase in cell therapies on the note of rising chronic diseases, the market is facing a bottleneck in the availability of plasmids and viral vectors; they are proven GMP-based raw materials required in the cell therapy process. 

Along with this, the obstacles in obtaining starting materials such as bone marrow, blood, and apheresis create a challenge for the market’s growth. Thus, the shortage of raw materials is restraining the global automated and closed-cell therapy processing systems market.

Opportunity:

Rising research and development activities in the pharmaceutical sector

Governments and major companies involved in the pharmaceutical industry are investing in research and development activities to enhance the discovery of novel treatments for various health conditions. The rising investment in R&D activities for the discovery of cell therapies will support the market’s growth by facilitating the discovery of novel automated and closed-cell therapies. Along with this, the rising research and development activities in the pharmaceutical sector are considered to generate noticeable revenue for the market.  

Covid-19 Impacts:

The World Health Organization (WHO) declared the outbreak of Coronavirus as a global pandemic in March 2020. The Covid-19 pandemic adversely affected the global economy by disrupting almost every industry. However, during this critical period, the automated and closed cell therapy processing systems market was mildly disturbed. The market faced numerous supply chain obstacles. 

The halt in the manufacturing process, lack of workforce, and disrupted business activities negatively impacted the global automated and closed cell therapy processing systems market. However, the pandemic forced the cell therapy market to focus on automation technology. The rising requirement for novel drugs to fight against Covid infection fueled the global market's demand for automated cell therapy processing systems.

Along with this, the rising requirement for stem cell therapy, natural killer cell therapy, and others during the pandemic boosted the market’s growth. Stem cell therapy is a vital segment of the automated and closed cell therapy processing systems market; the pharmaceuticals and medical sectors observed stem cell therapy as a promising treatment for Covid. All these advancements in the industry during the pandemic highlight the bright future of the automated and closed-cell therapy processing systems market.  

Workflow Insights:

The expansion segment dominates the market and generated more than 35% of the revenue share in 2022. Expansion is observed as one of the most critical stages during cell therapy manufacturing. The segment aims at genetic modification, which plays a crucial role in the research process.  

At the same time, the apheresis segment is expected to witness a significant increase during the forecast period. The apheresis segment includes the separation of different components from the donor’s blood. The rising focus on blood management solutions during cell therapy processing is boosting the segment’s growth. Apheresis offers better quality control of the components involved in automated cell therapy processing. However, the high cost of installing apheresis equipment may hinder the segment’s growth.  

Type Insights:

Non-stem cell therapy dominates the global automated and closed cell therapy processing systems market. The segment dominates with a revenue share of over 60% and is expected to maintain growth during the forecast period. The rising focus on developing non-stem cell-based treatments for curative purposes is considered to boost the segment’s growth. At the same time, the increasing prevalence of chronic diseases and neurological conditions is observed to promote the development of stem cell therapy during the forecast period.  

Scale Insights:

The Research and development (R&D) scale segment acquires almost 70% of the share in the global automated and closed cell therapy processing systems market. The rising number of innovation activities is supporting the segment’s growth. At the same time, the increasing government investment in R&D activities to enhance the discovery of novel processing systems is observed to fuel the development of the R&D scale segment in the market. The growing number of clinical trials worldwide is one of the major factors boosting the growth of the R&D scale segment. 

The commercial scale segment is projected to register significant growth during the forecast period due to rising companies’ focus on the development of advanced cell therapies to be utilized in cancer treatment. 

Regional Insights:

North America accounts for the dominating share of almost 46% in the global automated and closed cell therapy processing systems market. The rapid adoption of advanced automated cell therapy manufacturing systems in the region is considered a significant factor for the dominating share. Along with this, the growing number of research institutes and investments for the same are fueling the market’s growth in North America. The presence of major key players in the market has contributed to the advancements in the automated and closed cell therapy processing systems market. 

The automated and closed cell therapy processing systems market in the United Kingdom is projected to grow at a CAGR of 21.2% during the forecast period. The well-established pharmaceuticals market and rising research and development activities in the biotech sector are observed to support the development of the market in Europe. At the same time, the rising demand for customized medicines in the region will help the market to grow at a noticeable rate.  

Asia Pacific is expected to register a noticeable share in the automated and closed cell therapy processing systems market during the forecast period. A considerable potential of the pharmaceutical industry in India, Japan, China and South Korea is propelling the market’s growth in Asia Pacific. The rich potential in Japan for the automation of cell therapy manufacturing systems will supplement the market’s growth for Asia Pacific. Moreover, the advancements in the medicine development sector will fuel the growth of the automated and closed cell therapy processing systems market in Asia Pacific.  

The automated and closed cell therapy processing systems market in Latin America, the Middle East and Africa is witnessing steady growth owing to therapeutics platforms or systems development. Moreover, the rising demand for regenerative medicines is observed to boost the market’s growth during the forecast period.

Recent Developments:

• In February 2023, a clinical-stage biopharmaceutical company that develops innovative cell therapies, IASO Biotherapeutics, announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track (FT) Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation to its new BCMA CAR-T CT103A (Equecabtagene Autoleucel) drug. The drug can be utilized in the treatment of relapsed/refractory multiple myeloma (RRMM), which is a severe type of blood cancer that becomes non-responsive to cell therapy. 
• In February 2023, an independent organization for innovation and technology in the UK, Cell and Gene Therapy Catapult, announced its involvement in the development of a significant new life science campus in Stevenage. The company has planned to invest approximately 900 million Euros in the development of the new campus. The new campus aims to meet the enormous demand from life sciences companies.  
• In February 2023, a prominent cell therapy and regenerative medicine developer, Athersys Inc., announced that the U.S. Food and Drug Administration (FDA) granted a clinical type B meeting for protocol discussion. This step is intended to boost the company’s capabilities in the clinical trials for the advanced MASTERS-2.  
• In April 2022, one of the most extensive cancer research and treatment organizations in the U.S., City of Hope, planned to integrate Curate Biosciences’s Curate Cell Processing System into its workflow in order to manufacture investigational CAR-T cell immunotherapy. The company believes in achieving an innovative approach to T-cell separation by integrating this cell processing system. 
• In May 2021, a leading developer of cell therapies, GPB Scientific, announced adding $18 million in financial support for the commercialization of the Curate Cell Processing System by Curate Biosciences. This new generation cell processing system is expected to enable optimized development in the CAR-T and TCR programs. The Curate system also utilized the GPB’s Proprietary Deterministic Cell Separation Technology to deliver unmatched gene therapies for cancer treatment.  

Automated and Closed Cell Therapy Processing System Market Companies:

• Lonza
• BioSpherix
• Cellares
• Sortorius
• Cytiva
• ThermoGenesis Holdings Inc
• Thermo Fisher Scientific Inc

Segments Covered in the Report:

By Workflow

• Cryopreservation
• Fill-finish
• Separation
• Expansion
• Apheresis
• Others 

By Type

• Stem Cell Therapy
• Non-stem Cell Therapy

By Scale

• Commercial Scale
• R&D Scale

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa